INVESTIGATION OF MODIFIED SORAFENIB DERIVATIVES AS A TYROSINE KINASE INHIBITORS OF LEUKIMIA VIA MOLECULAR DOCKING. (2026). Frontier in Medical and Health Research, 4(5), 567-585. https://fmhr.net/index.php/fmhr/article/view/2904